CORGENTECH COMPLETES PATIENT ENROLLMENT PAIN DRUG TRIALS
Corgentech has announced that it has completed patient enrollment in three Phase II clinical trials of ALGRX 4975-one of three mid-to-late-stage non-opioid pain management drug candidates the company is developing-to evaluate this novel agent's ability to reduce post-surgical pain.
The three trials each enrolled approximately 40 patients who have either undergone cholecystectomy, hernia repair or total knee replacement surgery. The trials in hernia repair and cholecystectomy, or gallbladder removal, which is also a model for abdominal surgeries, were each conducted at single clinical sites. The trial in total knee replacement patients was conducted at two clinical sites. In all three trials, patients were randomized to receive either ALGRX 4975 or placebo, which was administered before closure of the surgical wound to reduce post-surgical pain, and thus reduce the need for opioid drugs and hasten recovery time.